Peroxisome proliferator activated receptor gamma and its activation in the treatment of insulin resistance and atherosclerosis: Issues and opportunities

Current Opinion in Cardiology

Volumn 18, Issue 6, 2003, Pages 479-485

  Beckman, Joshua ^a,b   Raji, Annaswamy ^a,b   Plutzky, Jorge ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Atherosclerosis; Insulin resistance; PPAR; Thiazolidinedione

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA TOCOPHEROL; ANTIDIABETIC AGENT; CALCIUM CHANNEL BLOCKING AGENT; CIGLITAZONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METFORMIN; NIFEDIPINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PIOGLITAZONE; ROSIGLITAZONE; SULFONYLUREA; TROGLITAZONE;

ANAMNESIS; ATHEROSCLEROSIS; CLINICAL TRIAL; CYTOKINE PRODUCTION; DIABETES MELLITUS; HUMAN; INSULIN RESISTANCE; PATHOGENESIS; PEROXISOME; PRIORITY JOURNAL; REVIEW;

CORONARY ARTERIOSCLEROSIS; DIABETES MELLITUS, TYPE 2; HUMANS; INSULIN RESISTANCE; RECEPTORS, CYTOPLASMIC AND NUCLEAR; THIAZOLIDINEDIONES; TRANSCRIPTION FACTORS;

EID: 0346878909     PISSN: 02684705     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001573-200311000-00009     Document Type: Review

References (73)

1. Beckman JA, Creager MA, Libby P: Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA 2002, 287:2570-2581. A thorough overview of issues regarding diabetic atherosclerosis.
2. Haffner SM, Lehto S, Ronnemaa T, et al.: Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998, 339:229-234. [see comments]
3. Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults: Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001, 285:2486-2497.
4. Management of dyslipidemia in adults with diabetes. American Diabetes Association. Diabetes Care 1998, 21:179-182.
5. Goldberg RB, Mellies MJ, Sacks FM, et al.: Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. The Care Investigators. Circulation 1998, 98:2513-2519.
6. Haffner SM, Alexander CM, Cook TJ, et al.: Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels: subgroup analyses in the Scandinavian Simvastatin Survival Study. Arch Intern Med 1999, 159:2661-2667.
7. Collins R, Armitage J, Parish S, et al.: MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003, 361:2005-2016. The wealth of data contained in the Heart Protection Study makes the original report of this study, and subgroup analysis such as this one on diabetes, worthwhile reading.
8. Chun BY, Dobson AJ, Heller RF: The impact of diabetes on survival among patients with first myocardial infarction. Diabetes Care 1997, 20:704-708.
9. Information for health care professionals [American Diabetes Association Web site]. 2003. Available at: http://www.ada.com.
10. Cavaghan MK, Ehrmann DA, Polonsky KS: Interactions between insulin resistance and insulin secretion in the development of glucose intolerance. J Clin Invest 2000, 106:329-333.
11. Henry RR: Thiazolidinediones. Endocrinol Metab Clin North Am 1997, 26:553-573.
12. Bliss M: The Discovery of Insulin, edn 3. Toronto: University of Toronto Press; 2000.
13. Yalow RS: SA B. Immunoassay of endogenous plasma insulin in man. 1960. Obes Res 1996, 4:579-582.
14. Wass JAH, Shalet SM, Gale EAM: Oxford Textbook of Endocrinology and Diabetes. Oxford; New York: Oxford University Press; 2002.
15. Turner NC, Clapham JC: Insulin resistance, impaired glucose tolerance and non-insulin-dependent diabetes, pathologic mechanisms and treatment: current status and therapeutic possibilities. Prog Drug Res 1998, 51:33-94.
16. Xiong W, Gray JD: The roles of receptor abnormalities in the pathogenesis and chronic complications of type 2 diabetes mellitus. Clin Invest Med 1999, 22:85-105.
17. Shulman GI: Cellular mechanisms of insulin resistance. J Clin Invest 2000, 106:171-176.
18. Reaven GM: Pathophysiology of insulin resistance in human disease. Physiol Rev 1995, 75:473-486.
19. Reaven GM: Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988, 37:1595-1607.
20. Ginsberg HN: Insulin resistance and cardiovascular disease. J Clin Invest 2000, 106:453-458.
21. Kendall D: Endocrinology, edn 4. Philadelphia: W.B. Saunders; 2001.
22. Carr ME: Diabetes mellitus: a hypercoagulable state. J Diabetes Complications 2001, 15:44-54.
23. Haffner SM: Patients with type 2 diabetes: the case for primary prevention. Am J Med 1999, 107:438-458.
24. Tuomilehto J, Lindstrom J, Eriksson JG, et al.: Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001, 344:1343-1350.
25. Yusuf S, Gerstein H, Hoogwerf B, et al.: Ramipril and the development of diabetes. JAMA 2001, 286:1882-1885.
26. Freeman DJ, Norrie J, Sattar N, et al.: Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation 2001, 103:357-362.
27. Azen SP, Peters RK, Berkowitz K, et al.: TRIPOD (TRoglitazone In the Prevention Of Diabetes): a randomized, placebo-controlled trial of troglitazone in women with prior gestational diabetes mellitus. Control Clin Trials 1998, 19:217-231.
28. Ziouzenkova O, Perrey S, Asatryan L, et al.: Lipolysis of triglyceride-rich lipoproteins generates PPAR ligands: Evidence for an antiinflammatory role for lipoprotein lipase. Proc Natl Acad Sci USA 2003, 100:2730-2735.
29. Chawla A, Lee CH, Barak Y, et al.: PPARdelta is a very low-density lipoprotein sensor in macrophages. Proc Natl Acad Sci USA 2003, 100:1268-1273.
30. McIntyre TM, Pontsler AV, Silva AR, et al.: Identification of an intracellular receptor for lysophosphatidic acid (LPA): LPA is a transcellular PPARgamma agonist. Proc Natl Acad Sci USA 2003, 100:131-136.
31. Kramer D, Raji A, Plutzky J: Prediabetes mellitus and its links to atherosclerosis. Curr Diab Rep 2003, 3:11-18.
32. Plutzky J, Libby P: Diabetic macrovascular disease: the glucose paradox? Circulation 2002, 106:2760-2763. An overview of the data regarding the impact of glucose control on cardiovascular events.
33. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group [published erratum appears in Lancet 1998, 352:1557]. Lancet 1998, 352:854-865.
34. Sasali A, Leahy JL: Is metformin cardioprotective? Diabetes Care 2003, 26:243-244.
35. Gale EA: Lessons from the glitazones: a story of drug development. Lancet 2001, 357:1870-1875.
36. Willson TM, Brown PJ, Sternbach DD, et al.: The PPARs: from orphan receptors to drug discovery. J Med Chem 2000, 43:527-550.
37. Lebovitz HE, Kreider M, Freed MI: Evaluation of liver function in type 2 diabetic patients during clinical trials: evidence that rosiglitazone does not cause hepatic dysfunction. Diabetes Care 2002, 25:815-821.
38. Scheen AJ: Hepatotoxicity with thiazolidinediones: is it a class effect? Drug Saf 2001, 24:873-888.
39. Ginsberg H, Plutzky J, Sobel BE: A review of metabolic and cardiovascular effects of oral antidiabetic agents: beyond glucose-level lowering. J Cardiovasc Risk 1999, 6:337-346.
40. Stumvoll M, Haring HU: Glitazones: clinical effects and molecular mechanisms. Ann Med 2002, 34:217-224. This article and Hauner [42] provide recent overviews of thiazolidinediones in greater detail.
41. Tontonoz P, Graves RA, Budavari AI, et al.: Adipocyte-specific transcription factor ARF6 is a heterodimeric complex of two nuclear hormone receptors, PPAR gamma and RXR alpha. Nucleic Acids Res 1994, 22:5628-5634.
42. Hauner H: The mode of action of thiazolidinediones. Diabetes Metab Res Rev 2002, 18(Suppl 2):S10-S15.
43. Finegood DT, McArthur MD, Kojwang D, et al.: Beta-cell mass dynamics in Zucker diabetic fatty rats. Rosiglitazone prevents the rise in net cell death. Diabetes 2001, 50:1021-1029.
44. Buchanan TA, Xiang AH, Peters RK, et al.: Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women. Diabetes 2002, 51:2796-2803. A very provocative study providing one example of efforts to see if diabetes can be delayed or even prevented, in this case with a thiazolidinedione.
45. Parulkar AA, Pendergrass ML, Granda-Ayala R, et al.: Nonhypoglycemic effects of thiazolidinediones. Ann Intern Med 2001, 134:61-71.
46. Raji A, Plutzky J: Insulin resistance, diabetes, and atherosclerosis: thiazolidinediones as therapeutic interventions. Curr Cardiol Rep 2002, 4:514-521.
47. Minamikawa J, Tanaka S, Yamauchi M, et al.: Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab 1998, 83:1818-1820.
48. Koshiyama H, Shimono D, Kuwamura N, et al.: Rapid communication: inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab 2001, 86:3452.
49. Kotchen TA, Zhang HY, Reddy S, et al.: Effect of pioglitazone on vascular reactivity in vivo and in vitro. Am J Physiol 1996, 270:R660-R666.
50. Caballero AE, Saouaf R, Lim SC, et al.: The effects of troglitazone, an insulin-sensitizing agent, on the endothelial function in early and late type 2 diabetes: a placebo-controlled randomized clinical trial. Metabolism 2003, 52:173-180.
51. Plutzky J: Peroxisome proliferator-activated receptors in endothelial cell biology. Curr Opin Lipidol 2001, 12:511-518.
52. Marx N, Schonbeck U, Lazar MA, et al.: Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells. Circ Res 1998, 83:1097-1103.
53. Law RE, Goetze S, Xi XP, et al.: Expression and function of PPARgamma in rat and human vascular smooth muscle cells. Circulation 2000, 101:1311-1318.
54. Hsueh WA, Jackson S, Law RE: Control of vascular cell proliferation and migration by PPAR-gamma: a new approach to the macrovascular complications of diabetes. Diabetes Care 2001, 24:392-397.
55. Ziouzenkova O, Perrey S, Marx N, et al.: Peroxisome proliferator- activated receptors in the vasculature. Curr Atheroscler Rep 2002, 4:59-64.
56. De Dios ST, Bruemmer D, Dilley RJ, et al.: Inhibitory activity of clinical thiazolidinedione peroxisome proliferator activating receptor-{gamma} ligands toward internal mammary artery, radial artery, and saphenous vein smooth muscle cell proliferation. Circulation 2003, 107:2548-2550.
57. Haffner SM, Greenberg AS, Weston WM, et al.: Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 2002, 106:679-684.
58. Marx N, Froehlich J, Siam L, et al.: Antidiabetic PPAR gamma-activator rosiglitazone reduces MMP-9 serum levels in type 2 diabetic patients with coronary artery disease. Arterioscler Thromb Vase Biol 2003, 23:283-288.
59. Marx N, Libby P, Plutzky J: Peroxisome proliferator-activated receptors (PPARs) and their role in the vessel wall: possible mediators of cardiovascular risk? J Cardiovasc Risk 2001, 8:203-210.
60. Varo N, Vicent D, Libby P, et al.: Elevated plasma levels of the atherogenic mediator soluble CD40 ligand in diabetic patients: a novel target of thiazolidinediones. Circulation 2003, 107:2664-2669.
61. Marx N, Imhof A, Froehlich J, et al.: Effect of rosiglitazone treatment on soluble CD40L in patients with type 2 diabetes and coronary artery disease. Circulation 2003, 107:1954-1957.
62. Pradhan AD, Manson JE, Rifai N, et al.: C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 2001, 286:327-334.
63. Tontonoz P, Nagy L, Alvarez JG, et al.: PPARgamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell 1998, 93:241-252.
64. Chawla A, Boisvert WA, Lee CH, et al.: A PPAR gamma-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis. Mol Cell 2001, 7:161-171.
65. Moore KJ, Rosen ED, Fitzgerald ML, et al.: The role of PPAR-gamma in macrophage differentiation and cholesterol uptake. Nat Med 2001, 7:41-47.
66. Chinetti G, Lestavel S, Bocher V, et al.: PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nat Med 2001, 7:53-58.
67. Schoonjans K, Staels B, Auwerx J: The peroxisome proliferator activated receptors (PPARS) and their effects on lipid metabolism and adipocyte differentiation. Biochim Biophys Acta 1996, 1302:93-109.
68. Niemeyer NV, Janney LM: Thiazolidinedione-induced edema. Pharmacotherapy 2002, 22:924-929.
69. Tang WH, Francis GS, Hoogwerf BJ, et al.: Fluid retention after initiation of thiazolidinedione therapy in diabetic patients with established chronic heart failure. J Am Coll Cardiol 2003, 41:1394-1398.
70. Masoudi FA, Wang Y, Inzucchi SE, et al.: Metformin and thiazolidinedione use in Medicare patients with heart failure. JAMA 2003, 290:81-85.
71. Berger J, Leibowitz MD, Doebber TW, et al.: Novel peroxisome proliferator-activated receptor (PPAR) gamma and PPARdelta ligands produce distinct biological effects. J Biol Chem 1999, 274:6718-6725.
72. Brooks DA, Etgen GJ, Rito CJ, et al.: Design and synthesis of 2-methyl-2-[4-(2-[5-methyl-2-aryloxazol-4-yl]ethoxy)phenoxy]propionic acids: a new class of dual PPARalpha/gamma agonists. J Med Chem 2001, 44:2061-2064.
73. Sauerberg P, Pettersson I, Jeppesen L, et al.: Novel tricyclic-alpha- alkyloxyphenylpropionic acids: dual PPARalpha/gamma agonists with hypolipidemic and antidiabetic activity. J Med Chem 2002, 45:789-804.